Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Letters

• Publication date

  2013-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2013.05.031PMID 23752064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations

  2012cited by this paper
• A differentially methylated single CpG-site is correlated with estrogen receptor alpha transcription.

  2012cited by this paper
• Binding of estrogen receptor alpha/beta heterodimers to chromatin in MCF-7 cells.

  2009cited by this paper
• ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

  2008cited by this paper
• Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.

  2007cited by this paper
• Pathways to tamoxifen resistance.

  2007cited by this paper
• Bad expression predicts outcome in patients treated with tamoxifen

  2007cited by this paper
• ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

  2006cited by this paper
• Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters.

  2006cited by this paper
• Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.

  2006cited by this paper
• ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors

  2006cited by this paper
• Estrogen Receptor (ER) β Modulates ERα-Mediated Transcriptional Activation by Altering the Recruitment of c-Fos and c-Jun to Estrogen-Responsive Promoters

  2006cited by this paper
• Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.

  2005cited by this paper
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005cited by this paper
• Clinical significance of estrogen receptor beta in breast cancer.

  2005cited by this paper
• Clinical significance of estrogen receptor β in breast cancer

  2005cited by this paper
• Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer

  2004cited by this paper
• Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

  2004cited by this paper
• Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.

  2004cited by this paper
• Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner.

  2004cited by this paper
• HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Estrogen Receptor β (ERβ) Level but Not Its ERβcx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer

  2004cited by this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cited by this paper
• Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

  2003cited by this paper
• Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.

  2003cited by this paper
• Reduced expression of oestrogen receptor β in invasive breast cancer and its re‐expression using DNA methyl transferase inhibitors in a cell line model

  2003cited by this paper
• Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma

  2003cited by this paper
• Expression of ERalpha and ERbeta in prostate cancer.

  2003cited by this paper
• Expression of ERα and ERβ in prostate cancer

  2003cited by this paper
• DNA methylation and cancer

  2002cited by this paper
• Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.

  2001cited by this paper
• ERβ Inhibits Proliferation and Invasion of Breast Cancer Cells.

  2001cited by this paper
• ER Inhibits Proliferation and Invasion of Breast Cancer Cells

  2001cited by this paper
• ER beta inhibits proliferation and invasion of breast cancer cells.

  2001cited by this paper
• Estrogen Response Elements Alter Coactivator Recruitment through Allosteric Modulation of Estrogen Receptor β Conformation*

  2001cited by this paper
• Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.

  2000cited by this paper
• Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.

  2000cited by this paper
• Selective loss of estrogen receptor β in malignant human colon

  2000cited by this paper
• Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.

  2000cited by this paper
• Selective loss of estrogen receptor beta in malignant human colon.

  2000cited by this paper
• Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer

  2000cited by this paper
• Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta.

  1999cited by this paper
• Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

  1999cited by this paper
• Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.

  1999cited by this paper
• Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β

  1999cited by this paper
• Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells

  1999cited by this paper
• Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

  1997cited by this paper
• Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.

  1996cited by this paper
• ER beta: identification and characterization of a novel human estrogen receptor.

  1996cited by this paper
• ERβ: Identification and characterization of a novel human estrogen receptor

  1996cited by this paper
• The Role of Estrogen in Mammary Carcinogenesis a

  1995cited by this paper
• Molecular mechanisms of action of steroid/thyroid receptor superfamily members.

  1994cited by this paper
• Estrogen receptor binding to nuclei from normal and neoplastic rat mammary tissues in vitro.

  1987cited by this paper
• Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.

  1984cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer

  2025cites this paper
• Antioxidant and Anticancer Activity of Vitis vinifera Extracts in Breast Cell Lines

  2024cites this paper
• Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.

  2023cites this paper
• Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression.

  2023cites this paper
• LC-HRMS/MS phytochemical profiling of Vernonia kotschyana Sch. Bip. ex Walp.: Potential involvement of highly-oxygenated stigmastane-type saponins in cancer cell viability, apoptosis and intracellular ROS production

  2022cites this paper
• The role of estrogen receptor beta in breast cancer

  2020cites this paper
• ASSESSMENT OF THE POTENTIAL ANTITUMOR EFFECTS OF GLINUS OPPOSITIFOLIUS (L.) AUG. DC. EXTRACTS

  2019cites this paper
• Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells

  2019cites this paper
• Modalités de régulation d’ERα36 et leurs conséquences sur la physiopathologie de la glande mammaire

  2019influential citation
• Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy

  2016cites this paper
• Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype.

  2015cites this paper
• Breast Cancer Epigenetics

  2015cites this paper
• Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies.

  2015cites this paper
• 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.

  2014cites this paper
• Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation

  2014cites this paper
• The many faces of estrogen signaling

  2014cites this paper
• Effects of Histone Deacetylase Inhibitors on Vitamin D Activity in Human Breast Cancer Cells

  2013cites this paper